GlassScriptPhysician profile
Megan Anne Schultz
NPI 1831551076
$3,340.04
in general payments reported to CMS, 2019-2025
36 companies · $417 in 2025
The $417 reported for 2025 was more than what a typical Internal Medicine provider received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $130 · 2020: $348 · 2021: $732 · 2022: $549 · 2023: $449 · 2024: $713 · 2025: $417.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,580.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,579.62 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $524.52 | 2019-2025 | Vraylar, Ubrelvy |
| Pfizer INC. | $404.89 | 2020-2025 | |
| Lilly USA, LLC | $316.28 | 2019-2025 | Mounjaro, Jardiance, Zepbound |
| Novo Nordisk INC | $273.93 | 2019-2025 | Wegovy, Ozempic |
| Glaxosmithkline, LLC. | $251.75 | 2020-2025 | Trelegy Ellipta, Arexvy, Shingrix |
| Boehringer Ingelheim Pharmaceuticals, INC. | $232.07 | 2020-2024 | Jardiance, Ofev |
| Amgen INC. | $224.19 | 2020-2025 | Repatha, Otezla, Evenity |
| Novartis Pharmaceuticals Corporation | $127.60 | 2022-2024 | |
| Bayer Healthcare Pharmaceuticals INC. | $91.91 | 2021-2025 | |
| Upsher-Smith Laboratories LLC | $83.59 | 2020-2022 | |
| Sumitomo Pharma America, INC. | $77.29 | 2023-2025 | Gemtesa |
| Sanofi-Aventis U.S. LLC | $72.66 | 2020-2021 | |
| Merck Sharp & Dohme LLC | $70.21 | 2019-2023 | Dificid |
| Teva Pharmaceuticals USA, INC. | $57.81 | 2021-2023 | Austedo Xr |
| Dynavax Technologies Corporation | $57.71 | 2024-2025 | Heplisav-B |
Show all 36 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbott Laboratories | $53.75 | 2021-2022 | |
| Esperion Therapeutics, INC. | $53.18 | 2021 | |
| Biohaven Pharmaceutical Holding Company LTD. | $39.80 | 2022 | |
| Axsome Therapeutics, INC. | $36.92 | 2024 | Auvelity |
| Biohaven Pharmaceuticals, INC. | $25.56 | 2021 | |
| Xeris Pharmaceuticals, INC. | $24.69 | 2024 | Gvoke Hypopen |
| Takeda Pharmaceuticals U.S.A., INC. | $21.71 | 2021 | |
| Csl Behring | $20.38 | 2019 | |
| Idorsia Pharmaceuticals US INC | $18.50 | 2022 | |
| Janssen Pharmaceuticals, INC | $17.93 | 2023 | Xarelto |
| Sage Therapeutics, LLC | $17.33 | 2025 | Zurzuvae |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $15.86 | 2019 | |
| Kowa Pharmaceuticals America, INC. | $15.81 | 2023 | Seglentis |
| Astrazeneca Pharmaceuticals LP | $15.32 | 2024 | Airsupra |
| Vanda Pharmaceuticals INC. | $15.00 | 2025 | Fanapt |
| Daiichi Sankyo INC. | $14.76 | 2019 | |
| E.R. Squibb & Sons, L.L.C. | $14.53 | 2022 | |
| Exact Sciences Corporation | $14.23 | 2023 | Cologuard Collection Kit |
| Corcept Therapeutics | $13.70 | 2019 | |
| Biogen, INC. | $12.80 | 2021 | |
| Allergan, INC. | $11.87 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Megan Schultz listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.